Detailed Information on Publication Record
2021
Silicane Derivative Increases Doxorubicin Efficacy in an Ovarian Carcinoma Mouse Model: Fighting Drug Resistance
FOJTŮ, Michaela, Jan BALVAN, Tomáš VIČAR, Hana HOLCOVÁ POLANSKÁ, Barbora PELTANOVÁ et. al.Basic information
Original name
Silicane Derivative Increases Doxorubicin Efficacy in an Ovarian Carcinoma Mouse Model: Fighting Drug Resistance
Authors
FOJTŮ, Michaela (203 Czech Republic, belonging to the institution), Jan BALVAN (203 Czech Republic, belonging to the institution), Tomáš VIČAR (203 Czech Republic, belonging to the institution), Hana HOLCOVÁ POLANSKÁ (203 Czech Republic, belonging to the institution), Barbora PELTANOVÁ (203 Czech Republic, belonging to the institution), Stanislava MATEJKOVA (203 Czech Republic), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Jiri STURALA (203 Czech Republic), Paula MAYORGA-BURREZO, Michal MASAŘÍK (203 Czech Republic, belonging to the institution) and Martin PUMERA (203 Czech Republic, guarantor)
Edition
ACS APPLIED MATERIALS & INTERFACES, WASHINGTON, AMER CHEMICAL SOC, 2021, 1944-8244
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
21001 Nano-materials
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 10.383
RIV identification code
RIV/00216224:14110/21:00120131
Organization unit
Faculty of Medicine
UT WoS
000674333400004
Keywords in English
2D nanomaterials; silicene; polysiloxane; nanosheets; targeted drug delivery; doxorubicin; ovarian cancer; drug resistance
Tags
International impact, Reviewed
Změněno: 7/2/2022 12:48, Mgr. Tereza Miškechová
Abstract
V originále
The development of cancer resistance continues to represent a bottleneck of cancer therapy. It is one of the leading factors preventing drugs to exhibit their full therapeutic potential. Consequently, it reduces the efficacy of anticancer therapy and causes the survival rate of therapy-resistant patients to be far from satisfactory. Here, an emerging strategy for overcoming drug resistance is proposed employing a novel two-dimensional (2D) nanomaterial polysiloxane (PSX). We have reported on the synthesis of PSX nanosheets (PSX NSs) and proved that they have favorable properties for biomedical applications. PSX NSs evinced unprecedented cytocompatibility up to the concentration of 300 mu g/mL, while inducing very low level of red blood cell hemolysis and were found to be highly effective for anticancer drug binding. PSX NSs enhanced the efficacy of the anticancer drug doxorubicin (DOX) by around 27.8-43.4% on average and, interestingly, were found to be especially effective in the therapy of drug-resistant tumors, improving the effectiveness of up to 52%. Fluorescence microscopy revealed improved retention of DOX within the drug-resistant cells when bound on PSX NSs. DOX bound on the surface of PSX NSs, i.e., PSX@DOX, improved, in general, the DOX cytotoxicity in vitro. More importantly, PSX@DOX reduced the growth of DOX-resistant tumors in vivo with 3.5 times better average efficiency than the free drug. Altogether, this paper represents an introduction of a new 2D nanomaterial derived from silicane and pioneers its biomedical application. As advances in the field of material synthesis are rapidly progressing, novel 2D nanomaterials with improved properties are being synthesized and await thorough exploration. Our findings further provide a better understanding of the mechanisms involved in the cancer resistance and can promote the development of a precise cancer therapy.
Links
LM2018129, research and development project |
| ||
MUNI/A/1246/2020, interní kód MU |
| ||
MUNI/A/1698/2020, interní kód MU |
| ||
NU21-08-00407, research and development project |
| ||
ROZV/28/LF17/2020, interní kód MU |
|